Spear Bio secures $45 million in oversubscribed Series A financing to accelerate product launch for protein research and disease diagnostics

FHS
July 31, 2024
11:53 am

WOBURN, Mass.–(BUSINESS WIRE)–Spear Bio Inc., a biotechnology company enabling the measurement of protein molecules down to dozens of copies with ubiquitous qPCR equipment, announced the successful closing of its $45 million Series A financing.

4DMT’s gene therapy reduced need for standard-of-care injections to treat age-associated vision loss

4D Molecular Therapeutics’ one-time gene therapy reduced the need for annual injections in patients with age-related blindness in a mid-stage trial. The company on Wednesday

September 20, 2024

Transradial PCI Finally Normalized in the U.S., Though Holdouts Remain

LONG BEACH, Calif. — Radial artery access has become the dominant approach for percutaneous coronary intervention (PCI), with real-world practice supporting the safety benefits of

May 3, 2024

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives | Psychedelic Invest

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression,

November 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.